Human epidermal growth factor receptor-2 (HER-2) is a transmembrane tyrosine kinase receptor that belongs to the epidermal growth factor receptor (EGFR) family, and is overexpressed in 25-30% of human breast cancers. HER-2 overexpression/amplification is associated with aggressive disease, short disease-free intervals and reduced survival. 1,2 In these patients with poor prognosis, the HER-2 protein is an important therapeutic target and its overexpression is found both in the primary and in metastatic sites. Research Group (BCIRG) 006. 13 In 2005, the initial results of these four trials, alongside a smaller Finnish trial, FinHer, 14 were released; these results were not only astonishing, but also highly consistent.
recombinant humanised monoclonal antibody directed against the extracellular domain of the HER-2 protein. There are several mechanisms by which trastuzumab exerts its action, including:
• induction of receptor downregulation/degradation; 4 • prevention of HER-2 ectodomain cleavage; 5 • inhibition of HER-2 kinase signal transduction via antibody-dependent cell-mediated cytotoxicity (ADCC); 6 and
• inhibition of angiogenesis. 7 As a single agent in the metastatic setting, overall response rates (complete plus partial responses) ranging from 15 to 30% have been reported. 8 In combination with chemotherapy -including taxanes and vinorelbine -response rates can range from 50 to 80%. 9 Research Group (BCIRG) 006. 13 In 2005, the initial results of these four trials, alongside a smaller Finnish trial, FinHer, 14 were released; these results were not only astonishing, but also highly consistent.
Despite differences in patient population and trial design -including chemotherapy regimen, the timing of trastuzumab initiation and the schedule and duration of trastuzumab administration -clinical benefit was observed across all trials, with 39-52% reduction in the recurrence rate and a 30% reduction in mortality. This degree of benefit in early breast cancer is the largest reported since the introduction of tamoxifen in hormone-receptor-positive disease.
Without much doubt, trastuzumab has had unfettered success in the metastatic and adjuvant setting; however, the reality is that not all patients will have an initial response, and in those who do, trastuzumab resistance often develops within one year of treatment initiation. 15 This is because tumorigenesis is a complex multi-step process, and in breast cancer therapeutic success will, indeed, need to rely on the targeting of multiple rather than single targets.
Many of the mechanisms of resistance to trastuzumab are not well characterised, but there are several hypotheses:
• altered receptor-antibody interaction with masking of HER-2 by a membrane-associated glycoprotein mucin-4 (MUC4); 16 • increased signalling from other HER receptors;
• phosphatase and tensin homologue (PTEN) inactivation or loss, resulting in increased Akt activity; 17 • reduced p27kip1; 18 • increased insulin-like growth factor receptor signalling; 19 and
• an inability of monoclonal antibodies to bind and inhibit p95 HER-2 (truncated forms of HER-2 without extracellular domains). 20 
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Beyond trastuzumab's initial success, effort is now being put into the development of novel HER-2-targeting agents, including other monoclonal antibodies, tyrosine kinase inhibitors (TKIs) and vaccines.
These agents are being evaluated in the metastatic setting in combination with trastuzumab, in combination with other cytotoxic chemotherapy or as single agents as a strategy to overcome trastuzumab resistance.
These novel drugs have variable but interesting properties, including:
• dual inhibition against EGFR and HER-2, such as lapatinib, pertuzumab and HKI-272;
• antiangiogenesis, such as bevacizumab or pazopanib;
• anti-mammalian target of rapamycin (mTOR) action, such as temsirolimus; and In the EGF10151 study, 22 Other studies, nevertheless, have been more promising. Storniolo et al. 26 found response rates of 29% in combining trastuzumab and lapatinib in a dose-escalation study, and Pegram et al., 27 in a phase I/II study, found an overall response rate of 54.1% in 37 metastatic HER-2-positive patients by combining trastuzumab with bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody.
Other current exciting studies include HKI-272, a highly selective Lapatinib has an effect on the development of central nervous system metastases.
Current Challenges in Human Epidermal Growth Factor Receptor-2-positive Breast Cancer inducing p27. 28 Pertuzumab (Omnitarg ® ) is a fully recombinant humanised monoclonal antibody that targets a different epitope of HER-2 and therefore makes it an attractive therapeutic option for trastuzumab-resistant patients. 29 An ansamycin antibiotic inhibitor of the heat-shock protein, HSP-90 (17-AAG) can interfere with multiple intracellular signal transduction pathways involving the Src family, Akt, bcr-abl, cyclin-dependent kinases and other transcription factors. 30 An interesting therapeutic strategy may also be in blocking the oestrogen receptor and HER-2 pathways because of the cross-talk that occurs between signal transduction and endocrine pathways. In the TAnDEM study, 31 In summary, the experience with trastuzumab thus far can only be described as a successful one, although -with the increasing use of trastuzumab in the adjuvant setting -the speculation is that trastuzumab resistance will be encountered more frequently in the future. Indeed, it is time to move forwards from this initial success and endeavour to refine therapeutic strategies for the use of novel molecularly targeted agents for trastuzumab-resistant patients; these should not only be clinically beneficial and scientifically sound, but also economically sustainable.
The optimal duration of trastuzumab treatment is still unknown and the question of whether to continue with or cease trastuzumab altogether at the point of disease progression remains empirically based. Furthermore, if trastuzumab is to continue, would a change in the companion chemotherapeutic agent be sufficient or must another molecularly targeted agent be added?
Translational oncology will hold the key to many of these unresolved issues by improving the understanding of tumour biology. As new molecular targets are increasingly identified and corresponding therapeutics are developed, the parallel development of translational tools that can help identify optimal candidates for each of the therapeutic approaches should also occur. Furthermore, it is only with well designed trials based on solid biological and molecular evaluations that the initial success with trastuzumab can lead to other successes in the exciting era of molecularly targeted therapy. ■
